Azithromycin, a questionable treatment for COVID-19.
作者信息
Belfaqeeh O, Janapala R N, Patel J, Alhashmi A, Pourmand A
机构信息
International Medicine Program, George Washington University School of Medicine and Health Sciences, Washington DC, USA.
International Medicine Program, George Washington University School of Medicine and Health Sciences, Washington DC, USA.
出版信息
Int J Antimicrob Agents. 2021 Mar;57(3):106280. doi: 10.1016/j.ijantimicag.2021.106280. Epub 2021 Jan 19.
Abstract
摘要
相似文献
1
Azithromycin, a questionable treatment for COVID-19.阿奇霉素，一种对新冠病毒病存疑的治疗方法。
Int J Antimicrob Agents. 2021 Mar;57(3):106280. doi: 10.1016/j.ijantimicag.2021.106280. Epub 2021 Jan 19.
2
Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.在 COVID-19 疫情危机期间洛匹那韦/利托那韦、羟氯喹和阿奇霉素的处方实践以及一家法国教学医院的药物干预措施。
Eur J Hosp Pharm. 2021 Sep;28(5):242-247. doi: 10.1136/ejhpharm-2020-002449. Epub 2020 Nov 25.
3
Can we use hydroxychloroquine to treat COVID-19 now?我们现在可以使用羟氯喹治疗新冠病毒疾病吗？
Int J Antimicrob Agents. 2021 Jan;57(1):106173. doi: 10.1016/j.ijantimicag.2020.106173.
4
Guillain-Barré syndrome as the first manifestation of SARS-CoV-2 infection.吉兰-巴雷综合征作为严重急性呼吸综合征冠状病毒2型感染的首发表现。
Neurologia (Engl Ed). 2020 Nov-Dec;35(9):710-712. doi: 10.1016/j.nrl.2020.07.001. Epub 2020 Jul 16.
5
Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.羟氯喹、阿奇霉素和洛匹那韦/利托那韦对 COVID-19 患者 QT 校正间期的影响。
J Electrocardiol. 2021 Jan-Feb;64:30-35. doi: 10.1016/j.jelectrocard.2020.11.012. Epub 2020 Nov 28.
6
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.氯喹、羟氯喹、阿奇霉素和洛匹那韦/利托那韦在 COVID-19 中的超适应证使用通过靶向 hERG 通道而延长 QT 间期。
Eur J Pharmacol. 2021 Feb 15;893:173813. doi: 10.1016/j.ejphar.2020.173813. Epub 2020 Dec 18.
7
The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.利好、弊端与骗局：当发表的内容瞬间影响新冠疫情治疗策略时
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.01127-20.
8
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.洛匹那韦-利托那韦与羟氯喹治疗轻度至中度 2019 冠状病毒病患者病毒清除和临床改善的比较。
Korean J Intern Med. 2021 Mar;36(Suppl 1):S253-S263. doi: 10.3904/kjim.2020.224. Epub 2020 Jun 16.
9
Biggest COVID-19 trial tests repurposed drugs first.规模最大的新冠病毒试验首先测试重新利用的药物。
Nat Biotechnol. 2020 May;38(5):510. doi: 10.1038/s41587-020-0528-x.
10
Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports.重新利用药物治疗 COVID-19 感染的疗效：病例报告。
Viral Immunol. 2024 Aug;37(6):298-307. doi: 10.1089/vim.2024.0034. Epub 2024 Aug 5.
引用本文的文献
1
Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID-19 by dual binding to IL-6/STAT3.临床数据挖掘揭示甘草-半夏可能通过双重结合 IL-6/STAT3 成为治疗中度 COVID-19 的一对草药。
Comput Biol Med. 2022 Jun;145:105457. doi: 10.1016/j.compbiomed.2022.105457. Epub 2022 Mar 26.
Zotero 插件